• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ZYME

    Zymeworks Inc.

    Subscribe to $ZYME
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

    IPO Year:

    Exchange: NYSE

    Website: zymeworks.com

    Peers

    $ALXO
    $ELOX
    $SBTX

    Recent Analyst Ratings for Zymeworks Inc.

    DatePrice TargetRatingAnalyst
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    11/1/2024$12.00Overweight → Equal Weight
    Wells Fargo
    3/21/2023$12.00Overweight
    Wells Fargo
    1/4/2023$10.00 → $8.00Neutral
    H.C. Wainwright
    12/20/2022$7.70 → $11.00Hold → Buy
    Jefferies
    11/1/2022$40.00 → $8.00Buy → Neutral
    H.C. Wainwright
    10/21/2022$8.00Outperform → Mkt Perform
    SVB Leerink
    10/4/2022$45.00 → $9.00Overweight
    Wells Fargo
    5/5/2022$14.00Neutral → Buy
    Guggenheim
    See more ratings

    Zymeworks Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

      Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of six posters with new preclinical data from its preclinical, development-stage, and clinical programs at the Americ

      4/25/25 1:00:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

      VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

      4/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time. The event will be webcast live with dial-in details and webcast replay

      4/17/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Participation in Upcoming Investor Conferences

      VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: Needham 24th Annual Virtual Healthcare Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on April 8 at 9:30 am Eastern Time (ET).Stifel 2025 Virtual Targeted Oncology Forum: Zymeworks' management will participate in virtual one-on

      3/26/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

      Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the acceptance of six abstracts for poster presentation at th

      3/25/25 4:30:35 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelinAcceleration of the planned investigational new drug (IND) application to mid-2025 for ZW251, an ADC engineered to target glypican-3 (GPC3) U.S. Food and Drug Administration (FDA) granted accelerated approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (HER2+) (IHC 3+) second-line biliary tract cancer (BTC)Reported $324.2 million in cash resources as of December 31, 2024, which when combined with certain anticipated

      3/5/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

      VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced achievement of a $14 million cash research milestone from GSK associated with a clinical milestone. About the Zymeworks and GSK Collaboration In April 2016, we entered into a platform technology transfer and license agreement with GSK to research, develop and commercialize up to six bispecific antibodies generated using our Azymetric™ platform. Under the

      2/26/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Participation in Upcoming Investor Conferences

      VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference: Zymeworks' management will participate in one-on-one meetings and present on March 4 at 10:30 am Eastern Time (ET) in Boston, MA.Leerink Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings

      2/25/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

      VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. With a proven track record in investment management gained over more than two de

      2/18/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

      VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its fourth quarter and full year 2024 financial results after market close on March 5, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 5, 2025 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in detai

      2/13/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Zymeworks Inc. SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zymeworks Inc.

      SCHEDULE 13G/A - Zymeworks Inc. (0001937653) (Subject)

      5/7/25 11:43:19 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Zymeworks Inc.

      SCHEDULE 13D/A - Zymeworks Inc. (0001937653) (Subject)

      4/8/25 4:24:32 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Zymeworks Inc.

      SCHEDULE 13D/A - Zymeworks Inc. (0001937653) (Subject)

      3/17/25 7:50:35 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Zymeworks Inc.

      S-8 - Zymeworks Inc. (0001937653) (Filer)

      3/5/25 4:45:06 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Zymeworks Inc.

      S-8 - Zymeworks Inc. (0001937653) (Filer)

      3/5/25 4:41:24 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Zymeworks Inc.

      10-K - Zymeworks Inc. (0001937653) (Filer)

      3/5/25 4:12:30 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zymeworks Inc. (0001937653) (Filer)

      3/5/25 4:08:20 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Zymeworks Inc.

      SCHEDULE 13D/A - Zymeworks Inc. (0001937653) (Subject)

      2/18/25 6:25:18 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Inc. filed SEC Form 8-K: Leadership Update

      8-K - Zymeworks Inc. (0001937653) (Filer)

      2/18/25 6:19:13 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zymeworks Inc.

      SCHEDULE 13G/A - Zymeworks Inc. (0001937653) (Subject)

      2/14/25 8:04:01 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Zymeworks Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/7/25 6:34:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,497,322 worth of shares (127,415 units at $11.75) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/2/25 7:02:09 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,227,309 worth of shares (97,349 units at $12.61) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      3/27/25 6:53:43 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,643,248 worth of shares (127,198 units at $12.92) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      3/24/25 5:45:12 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $2,866,553 worth of shares (228,463 units at $12.55) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      3/19/25 6:32:24 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $13,120,914 worth of shares (1,081,980 units at $12.13) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      3/13/25 7:35:15 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Nodelman Oleg claimed ownership of 15,720,161 shares (SEC Form 3)

      3 - Zymeworks Inc. (0001937653) (Issuer)

      2/18/25 3:48:01 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,963,538 worth of shares (141,429 units at $13.88) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      1/21/25 5:34:28 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $2,278,811 worth of shares (167,654 units at $13.59) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      1/15/25 6:12:17 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Zymeworks Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

      VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

      4/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

      VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. With a proven track record in investment management gained over more than two de

      2/18/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO

      Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research and new product development and remain Chair of the Board of Directors Augurex Life Sciences Corp., a world leader in the early diagnosis of autoimmune diseases and a pioneer in the field of 14-3-3η based diagnostics, today announced the appointment of Mr. Neil Klompas as President and Chief Executive Officer. Mr. Klompas will succeed Augurex's Co-founder Dr. Norma Biln, who has served as President and CEO since the Company began operations in 2008. Dr. Biln will continue to be an integral part of the company transitioning into the interim r

      8/6/24 7:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

      VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. "After an extensive search, we are delighted to have Leone Patterson join us at this exciting time as we plan for our next stage of growth and development at Zymeworks," said Kenneth Galbraith, Chair and CEO of Zymeworks. "She brings more than 20 years of public company biotec

      7/25/24 4:30:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

      VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. "Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company's development and growth," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "His exp

      3/28/24 6:00:00 AM ET
      $SNDX
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

      VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Alessandra Cesano to its board of directors effective February 8, 2024. Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks. "Zymeworks is honored to welcome Dr. Cesano to our board of directors," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "She brings more than 25 years of ex

      2/8/24 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces New Director Nominee

      VANCOUVER, British Columbia, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced that its board of directors will nominate Dr. Nancy Davidson for election to its board of directors at the Company's upcoming annual general meeting of stockholders to be held on December 7, 2023. "As the Company continues to execute on our strategy to support the approval and commercialization of zanidatamab while targeting five IND filings for new product candidates before the end of 2027, we are pleased to announce a significant proposed addition to our board of directors. With two prior

      10/16/23 4:30:18 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Appoints New Director

      VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Mr. Carlos E. Campoy to its board of directors effective as of June 30, 2023. Mr. Campoy brings extensive strategic and financial leadership experience in the pharmaceutical and biotechnology sectors to the Zymeworks board of directors. He was also appointed as a member of the audit committee and the nominating and corporate governance committee of the board of directors. Mr. Campoy succeeds Dr. Natalie Sacks, who will step down effective as of June 30 after a successful 6-y

      6/29/23 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors

      Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Mr. Miller brings extensive commercial, corporate and business development, and senior leadership experience in oncology to the Zymeworks board of directors. "Derek brings over two decades of strategic, operational and commercial leadership and deep experience in oncology to the Zymeworks board," said Kenneth Galbraith, Chair and CEO of Zymeworks. "His guidance and expertise will be an important asset for us as we work with our collaboration partners, Jazz Pharmaceutica

      4/10/23 8:30:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer

      Dr. Moore will lead Zymeworks' Early Research & Development Group responsible for advancing the Company's next-generation of multispecific antibody programs and antibody drug conjugate (ADC) programs into clinical studies Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer. Dr. Moore brings more than 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have

      6/27/22 8:30:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Zymeworks Inc. Financials

    Live finance-specific insights

    See more
    • Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time. The event will be webcast live with dial-in details and webcast replay

      4/17/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelinAcceleration of the planned investigational new drug (IND) application to mid-2025 for ZW251, an ADC engineered to target glypican-3 (GPC3) U.S. Food and Drug Administration (FDA) granted accelerated approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (HER2+) (IHC 3+) second-line biliary tract cancer (BTC)Reported $324.2 million in cash resources as of December 31, 2024, which when combined with certain anticipated

      3/5/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

      VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its fourth quarter and full year 2024 financial results after market close on March 5, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 5, 2025 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in detai

      2/13/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ZW220 and ZW251 at EORTC-NCI-AACR conferenceOur partner Jazz Pharmaceuticals presented new and updated clinical data at ESMO 2024 on zanidatamab highlighting its potential for the treatment of multiple HER2-positive (HER+) indicationsZymeworks to host in-person and virtual R&D day in New York City on December 12, 2024The Company has completed the initial $30 million of its Share Repurchase Program for 2,545,402 shares at an average price per share of $11.79 as of October 31, 2024Reported $374.9 million in cash resources as of September 30, 2024, which

      10/31/24 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

      VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https:/

      10/10/24 6:30:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results

      Reported $395.9 million in cash resources as of June 30, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Priority Review of the Biologics License Application (BLA) granted for zanidatamab as second-line (2L) treatment for HER2-positive biliary tract cancers (BTC) in the United States with target action date of November 29, 2024The European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for zanidatamab in 2L BTCZanidatamab BLA acceptance in China triggering $8 million milestone payment under the terms of Zymeworks' Asia-Pacific license and collaboration agreement with BeiGeneOur partner

      8/1/24 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

      VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 1, 2024 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at http://ir.

      7/11/24 6:30:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

      Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign e

      5/2/24 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

      VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 2, 2024 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at http://ir.zymewo

      4/11/24 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

      Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (US) with anticipated completion of regulatory submission in 1H 2024 by our partner, Jazz PharmaceuticalsInitiation of Phase 3 confirmatory trial for zanidatamab as first-line treatment in BTC by our partner Jazz PharmaceuticalsExpected submission of BLA for zanidatamab with the National Medical Products Administration (NMPA) in China for tr

      3/6/24 4:09:10 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Zymeworks Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 9:00:57 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 4:27:20 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zymeworks Inc.

      SC 13G - Zymeworks Inc. (0001937653) (Subject)

      11/13/24 4:30:24 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Zymeworks Inc.

      SC 13D - Zymeworks Inc. (0001937653) (Subject)

      2/22/24 7:01:34 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zymeworks Inc. (Amendment)

      SC 13G/A - Zymeworks BC Inc. (0001403752) (Subject)

      2/14/23 9:32:24 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zymeworks Inc. (Amendment)

      SC 13G/A - Zymeworks BC Inc. (0001403752) (Subject)

      2/6/23 2:36:14 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zymeworks Inc.

      SC 13G - Zymeworks Inc. (0001403752) (Subject)

      8/8/22 5:15:32 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Zymeworks Inc. (Amendment)

      SC 13D/A - Zymeworks Inc. (0001403752) (Subject)

      5/26/22 4:00:28 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Zymeworks Inc. (Amendment)

      SC 13D/A - Zymeworks Inc. (0001403752) (Subject)

      5/20/22 11:19:09 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Zymeworks Inc. (Amendment)

      SC 13D/A - Zymeworks Inc. (0001403752) (Subject)

      4/28/22 4:50:49 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Zymeworks Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/7/25 6:34:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,497,322 worth of shares (127,415 units at $11.75) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/2/25 7:02:09 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,227,309 worth of shares (97,349 units at $12.61) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      3/27/25 6:53:43 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,643,248 worth of shares (127,198 units at $12.92) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      3/24/25 5:45:12 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $2,866,553 worth of shares (228,463 units at $12.55) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      3/19/25 6:32:24 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $13,120,914 worth of shares (1,081,980 units at $12.13) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      3/13/25 7:35:15 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,963,538 worth of shares (141,429 units at $13.88) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      1/21/25 5:34:28 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $2,278,811 worth of shares (167,654 units at $13.59) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      1/15/25 6:12:17 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $2,974,819 worth of shares (225,119 units at $13.21) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      1/10/25 6:27:58 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Zymeworks Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zymeworks upgraded by Analyst with a new price target

      Analyst upgraded Zymeworks from Neutral to Overweight and set a new price target of $18.00

      12/16/24 6:40:30 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Zymeworks from Market Perform to Outperform and set a new price target of $25.00 from $10.00 previously

      11/7/24 6:47:25 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Zymeworks from Overweight to Equal Weight and set a new price target of $12.00

      11/1/24 7:40:43 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo resumed coverage on Zymeworks with a new price target

      Wells Fargo resumed coverage of Zymeworks with a rating of Overweight and set a new price target of $12.00

      3/21/23 7:47:46 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Zymeworks with a new price target

      H.C. Wainwright reiterated coverage of Zymeworks with a rating of Neutral and set a new price target of $8.00 from $10.00 previously

      1/4/23 10:32:48 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Jefferies with a new price target

      Jefferies upgraded Zymeworks from Hold to Buy and set a new price target of $11.00 from $7.70 previously

      12/20/22 7:52:53 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Zymeworks from Buy to Neutral and set a new price target of $8.00 from $40.00 previously

      11/1/22 9:37:01 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Zymeworks from Outperform to Mkt Perform and set a new price target of $8.00

      10/21/22 7:46:16 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo resumed coverage on Zymeworks with a new price target

      Wells Fargo resumed coverage of Zymeworks with a rating of Overweight and set a new price target of $9.00 from $45.00 previously

      10/4/22 7:16:53 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Guggenheim with a new price target

      Guggenheim upgraded Zymeworks from Neutral to Buy and set a new price target of $14.00

      5/5/22 7:30:15 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care